A 70-year-old Rhode Island man is the first person in the world to receive a recently FDA approved Alzheimer’s drug – the first to gain FDA approval in 20 years.
850WFTL spoke with board certified Neurologist Dr. Mark Goldstein, Medical Director for JEM Research Institute in Atlantis, Florida, right here in Palm Beach County and he says the new drug, Aduhelm, is a potential game changer because it targets the cause of Alzheimer’s not the symptoms. Therefore, Aduhelm, over time, is designed to slow or prevent further memory loss.
If you are interested in the new Alzheimer’s drug, listen to my full interview with Dr. Goldstein here.
According to the FDA, “Aduhelm is an amyloid beta-directed antibody indicated for the treatment of Alzheimer’s disease. It is approved under the accelerated approval pathway, which provides patients suffering from a serious disease earlier access to drugs when there is an expectation of clinical benefit despite some uncertainty about the clinical benefit of the drug.
Accelerated approval is based upon the drug’s ability to reduce amyloid beta plaque in the brain. Doctors can detect the presence of this plaque in a patient’s brain via a PET Scan.
The new Alzheimer’s drug is administered intravenously once a month and its affects are measured over time, not immediately. Dr. Goldstein says you may be a candidate for Aduhelm if you have family history of Alzheimer’s and are not yet exhibiting symptoms such as memory loss and if you have already been diagnosed with Alzheimer’s disease.
Contact Dr. Mark Goldstein and the JEM Research Institute here.